L'Oréal has increased its stake in Galderma to 20%, signaling continued strategic confidence in the aesthetics company's injectables and device portfolio. The move reflects broader industry consolidation around premium brands and integrated beauty-pharma platforms, where toxin, filler, and energy-device capabilities command pricing power and loyalty-program leverage.